

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2917232 T3**

-
- (51) Int.Cl.: **C 07 K 14/755 (2006.01)** **A 61 K 38/00 (2006.01)** **A 61 K 38/37 (2006.01)**
A 61 K 39/00 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2017-06-12**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2017-03-01**
- (86) Europæisk ansøgning nr.: **13795002.8**
- (86) Europæisk indleveringsdag: **2013-11-11**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-09-16**
- (86) International ansøgning nr.: **IB2013060060**
- (87) Internationalt publikationsnr.: **WO2014072958**
- (30) Prioritet: **2012-11-12 GB 201220328** **2013-09-19 GB 201316660**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV
MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Apitope International NV, Campus Diepenbeek , Agoralaan, 3590 Diepenbeek, Belgien**
- (72) Opfinder: **WRAITH, David, c/o School of Cellular and Molecular Medicine, University of Bristol, Medical Sciences
Building, Bristol BS8 1TD, Storbritannien**
**STREETER, Heather, c/o School of Cellular and Molecular Medicine, University of Bristol, Medical Sciences
Building, Bristol BS8 1TD, Storbritannien**
- (74) Fuldmægtig i Danmark: **RWS Group, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9
9FG, Storbritannien**
- (54) Benævnelse: **FAKTOR VIII-AFLEDTE PEPTIDER TIL ANVENDELSE TIL BEHANDLING AF HÆMOFILI A**
- (56) Fremdragne publikationer:
WO-A1-2009/071886
WO-A2-2009/095646
WO-A2-2010/133834
FR-A1- 2 842 812

DESCRIPTION

FIELD OF THE INVENTION

[0001] The present invention relates to peptides, at least part of which is derivable from factor VIII (FVIII). The peptides can be used to reduce or prevent factor VIII inhibitor antibody formation, for example in haemophilia A treatment and acquired haemophilia.

BACKGROUND TO THE INVENTION

HAEMOPHILIA

[0002] Haemophilia belongs to a group of inheritable blood disorders that includes haemophilia A, haemophilia B (Christmas disease) and Von Willebrand's disease.

[0003] In haemophilia, the blood's ability to clot is severely reduced because an essential clotting factor is partly or completely missing, resulting in increased bleeding time.

[0004] Haemophilia A is a deficiency of the clotting factor VIII, whereas Haemophilia B is a deficiency of clotting factor IX. In both diseases, the faulty gene is found on the X chromosome, so the conditions are X-linked. Haemophilia A is five times more common than haemophilia B.

[0005] Haemophilia is a lifelong inherited genetic condition, which affects females as carriers and males who inherit the condition. About a third of new diagnoses are where there is no previous family history. It appears world-wide and occurs in all racial groups. About 6,000 people are affected with haemophilia in the UK.

[0006] Haemophiliacs bleed for a prolonged period following injury. External injuries such as cuts and grazes do not usually pose serious problems: it is often possible to stop bleeding by applying a degree of pressure and covering the affected area (e.g with a plaster).

[0007] The main problem is internal bleeding into joints, muscles and soft tissues, which can occur spontaneously. Internal bleeding, such as haemorrhages into the brain, is very difficult to manage and can be fatal. Repeated bleeding in the joints causes acute pain and can cause arthritis and/or long-term joint damage leading to disability.

[0008] Treatment for haemophilia is usually by replacement of the missing clotting factor. In mild or moderate haemophilia injections may be given at the time a bleed occurs (on-demand therapy). However, in severe haemophilia regular prophylactic injections are given to help the blood to clot and minimise the likelihood of long term joint damage.

[0009] A potentially serious complication of coagulation factor replacement therapy for haemophilia A is the development of antibodies that neutralise the procoagulant function of factor VIII. Factor VIII inhibitors occur in approximately 25% of those with severe haemophilia A. Since patients with congenital haemophilia A can be genetically deficient in FVIII, the synthesis of inhibitors is an alloimmune response to the foreign protein administered to prevent or treat bleeding episodes.

[0010] CD4+ T cells play a central role in the immune response to FVIII. After being taken up by antigen-presenting cells (APCs), FVIII undergoes proteolytic degradation into peptide fragments (Reding et al (2006) Haemophilia 12(supp 6) 30-36). These peptides are then presented on the surface of the APC in association with MHC class II molecules. This complex is then recognised by the T cell receptor of a CD4+ cell specific for FVIII. In the presence of the appropriate costimulatory signals, this recognition ultimately causes the CD4+ cell to direct the synthesis of antibodies by B cells.

[0011] The incidence of inhibitor formation initially increases with the number of factor VIII treatments, but appears to plateau after 50-100 exposure days. Inhibitor formation is much more common in severe haemophilia than in moderate or mild disease and some molecular defects, most clearly large deletions and nonsense mutations in the factor VIII light chain, appear to predispose to inhibitor formation. Parameters such as the concentration, type (purified or recombinant) of replacement factor, and

treatment history may also affect the likelihood of antibody production.

[0012] The management of haemophilia patients with inhibitors is an ongoing challenge. Immune tolerance induction (ITI) using a desensitization technique is successful in some patients with alloantibodies against factor VIII. This therapeutic approach requires ongoing exposure to factor replacement therapy, so is a long-term strategy.

[0013] Although ITI can be successful, a significant proportion (about 30%) of patients fails to respond to ITI. Patients with high inhibitor titres are much less likely to respond to treatment. Another significant contributing factor is age at the start of commencing ITI, with greatly decreased success rates when the patient is older than 20 (Hay et al (2005) *Seminars in Thrombosis and Hemostasis* 32:15-21)

[0014] When ITI therapy is unsuccessful, the inhibitor generally persists for life, and because such patients are usually high-responders, it is necessary to treat episodes of bleeding with FVIII bypassing products, such as activated prothombin complex concentrates (FEIBA™), and recombinant-activated FVII. However, the use of such agents is associated with adverse events such as disseminated intravascular coagulation, acute myocardial infarction, pulmonary embolus and thromboses (Acharya and DiMichele (2006) *Best Practice & Research Clinical Haematology* 19:51-66).

[0015] Immunosuppressive therapy is sometimes used for patients who fail to response to ITI. Treatment includes administration of immunosuppressive drugs such as cyclophosphamide, prednisone, azathioprine and cyclosporine which non-specifically target the immune system. These treatments can have side-effects associated with general immunosuppression.

[0016] There is renewed interest on selective B cell depletion using Rituximab™, a humanised monoclonal antibody to B cell CD20 antigen. However, infusion reactions, serum sickness and opportunistic infections have occurred in some children treated with this drug (DiMichele (2007) *J Thromb Haemost* 5:143-50).

ACQUIRED HAEMOPHILIA

[0017] Acquired haemophilia is a rare autoimmune condition which affects between 1 and 4 people in every million. In this condition, subjects who are not born with haemophilia develop antibodies against one of the clotting factors such as factor VIII. It is thought that pregnancy and autoimmune diseases such as rheumatoid arthritis and cancer may increase the risk of developing acquired haemophilia. Although there are differences in the underlying immune mechanisms leading to their production, the clinical manifestations of FVIII inhibitors produced in response to coagulation factor replacement therapy and those produced in acquired haemophilia are similar.

[0018] Acquired haemophilic patients have a mortality rate that approaches 25%, partly because of the association of acquired inhibitors with severe bleeding complications. The therapy of acquired autoantibody inhibitors is based primarily on the need to control or prevent acute hemorrhagic complications, which frequently are life and limb threatening and secondarily to eradicate the autoantibody to restore normal coagulation.

[0019] Some bleeds associated with low titre autoantibody inhibitors (< 5 Bethesda Units) may be treated effectively with FVIII concentrates administered at high doses. Porcine FVIII concentrate was formerly considered a critical first-line therapy for acquired haemophilia-related bleeding since it was the only replacement therapy that provided an opportunity to actually measure post-infusion FVIII coagulation activity levels in the laboratory. The product was removed from the marketplace in 2004 because of contamination of the porcine plasma pools by porcine parvovirus. Now, "bypassing" agents are most commonly used, but potential risks of thrombogenicity exist and there is only about 80% efficacy for each product. Plasma exchange via plasmapheresis and extracorporeal immunoadsorption may be necessary to temporarily reduce the inhibitor titer enough for bypassing agents or FVIII replacement to provide adequate hemostasis.

[0020] Eradication of autoantibody inhibitors depends on immunosuppressive measures, such as: (1) administration of corticosteroids with 30%-50% efficacy in 3-6 weeks; (2) use of cytotoxic and myelosuppressive chemotherapeutic agents, e.g., cyclophosphamide, cyclosporine, 2-chlorodeoxyadenosine; (3) immunomodulation with intravenous immunoglobulin; and (4) selective B-lymphocyte depletion with rituximab. Rituximab™ responders may require concurrent use of steroids and relapses may respond to retreatment.

[0021] Thus, all currently available methods for reducing alloantibody production associated with haemophilia A treatment, and autoantibody production in acquired haemophilia, have shortcomings. There is therefore a need for improved methods to address

the issue of anti-FVIII antibodies in haemophilia A and acquired haemophilia.

[0022] The present inventors have found that it is possible to prevent FVIII inhibitor antibody formation by pre-tolerising the patient with FVIII-derived peptides and to treat conditions such as haemophilia by administration of FVIII-derived peptides in order to reduce FVIII inhibitor antibodies.

SUMMARY OF ASPECTS OF THE INVENTION

[0023] The first aspect of the present invention, therefore, relates to a peptide, at least part of the sequence of which is derivable from FVIII, which is capable of inducing or restoring tolerance to FVIII.

[0024] In a first embodiment of the first aspect of the invention, the invention provides a peptide comprising the FVIII-derived sequence DNIMVTFRNQASRPY which has one of the following sequences:

Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys (SEQ ID No. 17)

Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu (SEQ ID No. 18)

Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys (SEQ ID No. 19)

Lys-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys (SEQ ID No. 25)

Lys- Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu (SEQ ID No. 26)

Lys- Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys (SEQ ID No. 27)

Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys (SEQ ID No. 29)

Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu (SEQ ID No. 30) and

Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys (SEQ ID No. 31).

[0025] In a second embodiment, the present invention provides a peptide comprising the FVIII-derived sequence PRCLTRYSSFVNME which has one of the following sequences:

Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys (SEQ ID No. 1)

Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu (SEQ ID No. 2)

Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys (SEQ ID No. 3)

Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys (SEQ ID No. 5)

Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys (SEQ ID No. 7)

Lys-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys (SEQ ID No. 9)

Lys- Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu (SEQ ID No. 10)

Lys- Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys (SEQ ID No. 11) and

Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys (SEQ ID No. 13).

[0026] In a second aspect, the present invention provides a composition comprising a plurality of peptides, including one or more peptide(s) according to the first aspect the invention.

[0027] The composition may comprise at least one peptide according to the first embodiment and at least one peptide according to the second embodiment of the first aspect of the invention.

[0028] The composition may comprise a peptide having SEQ ID No. 1 and a peptide having SEQ ID No. 17.

[0029] The composition may be in the form of a kit, in which the plurality of peptides are provided separately for separate, subsequent, sequential or simultaneous administration.

[0030] The peptide or a composition of the invention may be for use in suppressing, reducing, or preventing the development of factor VIII inhibitor antibodies.

[0031] Described herein is also the use of such a peptide or composition in the manufacture of a medicament to suppress, reduce or prevent the development of factor VIII inhibitor antibodies.

[0032] Described herein is also a method for suppressing, preventing or reducing the development of Factor VIII inhibitor antibodies in a subject, which comprises the step of administration of such a peptide or composition to the subject.

[0033] The subject may be deficient in FVIII. In particular the subject may have haemophilia A, and may be, or be about to, undergo factor VIII replacement therapy.

[0034] Alternatively the subject may have, or be at risk from contracting, acquired haemophilia.

[0035] Factor VIII inhibitors are found more frequently in individuals expressing HLA-DR2. The subject treated by the method of the invention may therefore be HLA-DR2 positive.

DESCRIPTION OF THE FIGURES

[0036]

Figure 1: Solubility of modified FVIII peptides

A total of 32 peptides were tested: 16 of which were based on the FVIII peptide PRCLTRYSSFVNME ("PRCLT") (SEQ ID No. 1,2,3,4,5,6,7,8,9,10,11,12,13); and 16 of which were based on the FVIII peptide DNIMVTFRNQASRPY ("DNIMV") (SEQ ID No. 17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32). Their solubility was tested relative to an unrelated control peptide (4Y) which is known to be sufficiently soluble for application as a tolerising antigen. In the diagram, green represents a peptide which is at least as soluble as 4Y, orange represents a peptide which is not quite as soluble as 4Y but is fairly close, and red represents a peptide which is not as soluble as 4Y. Peptides coded green were as soluble as control peptide 4Y, peptides coded red were poorly soluble, and one peptide coded amber had intermediate solubility.

Figure 2: Solubility of tagged peptides in aqueous solution.

The concentration of peptide in solution following dissolution in DMSO (control) or PBS was determined spectrophotometrically and compared to the expected value of 4mg/mL. A greater disparity between the actual and expected concentration corresponds to lower relative solubility.

Figure 3: The tagged peptides act as apitopes

Antigen presentation assays with fresh and fixed antigen presenting cells were conducted to investigate whether the tagged peptides, like the parent peptides PRCLT and DNIMV, are capable of binding to an MHC molecule and being presented to a T cell without antigen processing. (a) PRCLT peptides; (b) DNIMV peptides.

Figure 4: Peptides having SEQ ID 1 and SEQ ID 2 regulate a T cell response to PRCLT

The figure shows recall responses from HLA-DR2 transgenic mice treated with either SEQ ID 1, SEQ ID 2 or control (PBS) and primed with PRCLT. T cell stimulation indices are shown across a range of peptide concentrations and against FVIII and the control PPD

Figure 5: Peptides having SEQ ID 17 and SEQ ID 18 regulate a T cell response to DNIMV.

The figure shows recall responses from HLA-DR2 transgenic mice treated with either SEQ ID 17, SEQ ID 18 or control (PBS) and primed with DNIMV. T cell stimulation indices are shown across a range of peptide concentrations and against FVIII and the control PPD.

Figure 6: Peptides having SEQ ID 1 and SEQ ID 17 regulate a T cell response to their parental peptides.

The figure shows recall responses from HLA-DR2 transgenic mice treated with either SEQ ID 1 or SEQ ID 17 or control (PBS) and primed with PRCLT and DNIMV and recalled in vitro with PRCLT, DNIMV or FVIII. T cell stimulation indices are shown across a

range of peptide concentrations and against FVIII. There is a significant inhibition of T cell responses to the parental peptides.

Figure 7: A combination of a peptide having SEQ ID No. 1 and a peptide having SEQ ID No. 17 inhibits anti-FVIII antibody production *in vivo*.

The figure shows end point anti-FVIII antibody titres of mice treated with a combination of SEQ ID 1 and SEQ ID 17 (or PBS control) and immunised with 8 weekly FVIII immunisations

Figure 7a: results at day28

Figure 7b: results at day56

FIGURE 8: A combination of a peptide having SEQ ID No. 1 and a peptide having SEQ ID No. 17 prevents neutralising anti-FVIII antibody production *in vivo* upon FVIII exposure

The figure shows the levels of neutralising anti-FVIII antibodies in mice treated with a combination of SEQ ID 1 and SEQ ID 17 (or PBS control) prior to and during 8 weekly FVIII immunisations. At day56 there is a significant reduction of neutralising antibodies in peptide treated mice.

Figure 9: A combination of a peptide having SEQ ID No. 1 and a peptide having SEQ ID No. 17 inhibits T cell responses to FVIII.

The figure shows recall responses from HLA-DR2 transgenic mice treated with a combination of SEQ ID 1 and, SEQ ID 17 or control (PBS) and primed with DNIMV and PRCLT. T cell stimulation indices are shown across a range of FVIII concentrations.

FIGURE 10: A combination of a peptide having SEQ ID No. 1 and a peptide having SEQ ID No. 17 suppresses neutralising anti-FVIII antibody generation in a therapeutic animal model with an ongoing FVIII immune response

The figure shows the levels of neutralising anti-FVIII antibodies in mice treated with a combination of SEQ ID 1 and SEQ ID 17 or prostatic acid phosphatase (PAP) 133-152 control peptide (sequence as described in PCT/US2006/031961, SEQ ID No. 15) after a FVIII immune response and anti-FVIII antibody production was induced. Mice received peptide treatment three weeks after rFVIII immunisation and prior to a boost immunization with rFVIII. Two weeks after the FVIII boost immunisation (week 7), there is a significant reduction of neutralizing anti-FVIII antibodies in peptide treated mice which is maintained during the course of the experiment for up to week 13.

DETAILED DESCRIPTION

PEPTIDE

[0037] The present invention relates to a peptide.

[0038] The term "peptide" is used in the normal sense to mean a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the α -amino and carboxyl groups of adjacent amino acids. The term includes modified peptides and synthetic peptide analogues.

[0039] The peptide of the present invention may be made using chemical methods (Peptide Chemistry, A practical Textbook. Mikos Bodansky, Springer-Verlag, Berlin.). For example, peptides can be synthesized by solid phase techniques (Roberge JY et al (1995) Science 269: 202-204), cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins Structures And Molecular Principles, WH Freeman and Co, New York NY). Automated synthesis may be achieved, for example, using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

[0040] The peptide may alternatively be made by recombinant means, or by cleavage of a peptide from factor VIII followed by modification of one or both ends. The composition of a peptide may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure).

[0041] For practical purposes, there are various other characteristics which the peptide may show. For example, it is important that the peptide is sufficiently stable *in vivo* to be therapeutically useful. The half-life of the peptide *in vivo* may be at least 10 minutes, 30 minutes, 4 hours, or 24 hours.

[0042] The peptide may also demonstrate good bioavailability *in vivo*. The peptide may maintain a conformation *in vivo* which enables it to bind to an MHC molecule at the cell surface without due hindrance.

APITOPES

[0043] In an adaptive immune response, T lymphocytes are capable of recognising internal epitopes of a protein antigen. Antigen presenting cells (APC) take up protein antigens and degrade them into short peptide fragments. A peptide may bind to a major histocompatibility complex (MHC) class I or II molecule inside the cell and be carried to the cell surface. When presented at the cell surface in conjunction with an MHC molecule, the peptide may be recognised by a T cell (via the T cell receptor (TCR)), in which case the peptide is a T cell epitope.

[0044] An epitope is thus a peptide derivable from an antigen which is capable of binding to the peptide-binding groove of a MHC class I or II molecule and be recognised by a T cell.

[0045] The minimal epitope is the shortest fragment derivable from an epitope, which is capable of binding to the peptide-binding groove of a MHC class I or II molecule and being recognised by a T cell. For a given immunogenic region, it is typically possible to generate a "nested set" of overlapping peptides which act as epitopes, all of which contain the minimal epitope but differ in their flanking regions.

[0046] By the same token, it is possible to identify the minimal epitope for a particular MHC molecule:T cell combination by measuring the response to truncated peptides. For example if a response is obtained to the peptide comprising residues 1-15 in the overlapping library, sets which are truncated at both ends (i.e. 1-14, 1-13, 1-12 etc. and 2-15, 3-15, 4-15 etc.) can be used to identify the minimal epitope.

[0047] The present inventors have previously determined that there is a link between the capacity of a peptide to bind to an MHC class I or II molecule and be presented to a T cell without further antigen processing, and the peptide's capacity to induce tolerance *in vivo* (WO 02/16410). If a peptide is too long to bind the peptide binding groove of an MHC molecule without further processing (e.g. trimming), or binds in an inappropriate conformation then it will not be tolerogenic *in vivo*. If, on the other hand, the peptide is of an appropriate size and conformation to bind directly to the MHC peptide binding groove and be presented to a T cell, then this peptide can be predicted to be useful for tolerance induction.

[0048] It is thus possible to investigate the tolerogenic capacity of a peptide by investigating whether it can bind to an MHC class I or II molecule and be presented to a T cell without further antigen processing *in vitro*.

[0049] The peptides of the present invention are apitopes (Antigen Processing-Independent epiTOPES) in that they are capable of binding to an MHC class II molecule and stimulating a response from factor VIII specific T cells without further antigen processing. Such apitopes can be predicted to cause tolerance to FVIII, following the rule-based method described in WO 02/16410.

[0050] A peptide of the present invention may be any length that is capable of binding to an MHC class I or II molecule without further processing. Typically, the peptide of the present invention is capable of binding MHC class II.

[0051] Peptides that bind to MHC class I molecules are typically 7 to 13, more usually 8 to 10 amino acids in length. The binding of the peptide is stabilised at its two ends by contacts between atoms in the main chain of the peptide and invariant sites in the peptide-binding groove of all MHC class I molecules. There are invariant sites at both ends of the groove which bind the amino and carboxy termini of the peptide. Variations in peptide length are accommodated by a kinking in the peptide backbone, often at proline or glycine residues that allow the required flexibility.

[0052] Peptides which bind to MHC class II molecules are typically between 8 and 20 amino acids in length, more usually between 10 and 17 amino acids in length, and can be longer (for example up to 40 amino acids). These peptides lie in an extended conformation along the MHC II peptide-binding groove which (unlike the MHC class I peptide-binding groove) is open at both ends. The peptide is held in place mainly by main-chain atom contacts with conserved residues that line the peptide-binding groove.

PEPTIDE SEQUENCES

[0053] The first embodiment of the invention relates to a peptide comprising a FVIII-derived sequence. FVIII-derived sequences which were investigated in the Examples have the following sequences

SEQ ID No. 1: Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys
 SEQ ID No. 2: Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu
 SEQ ID No. 3: Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys
 SEQ ID No. 4: Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Glu
 SEQ ID No. 5: Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys
 SEQ ID No. 6: Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu
 SEQ ID No. 7: Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys
 SEQ ID No. 8: Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Glu
 SEQ ID No. 9: Lys-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys
 SEQ ID No. 10: Lys-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu
 SEQ ID No. 11: Lys-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys
 SEQ ID No. 12: Lys-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Glu
 SEQ ID No. 13: Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys
 SEQ ID No. 14: Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu
 SEQ ID No. 15: Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys
 SEQ ID No. 16: Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Glu
 SEQ ID No. 17: Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys
 SEQ ID No. 18: Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu
 SEQ ID No. 19: Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys
 SEQ ID No. 20: Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu
 SEQ ID No. 21: Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys
 SEQ ID No. 22: Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu
 SEQ ID No. 23: Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys
 SEQ ID No. 24: Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu
 SEQ ID No. 25: Lys-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys
 SEQ ID No. 26: Lys-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu
 SEQ ID No. 27: Lys-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys
 SEQ ID No. 28: Lys-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu
 SEQ ID No. 29: Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys
 SEQ ID No. 30: Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu
 SEQ ID No. 31: Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys
 SEQ ID No. 32: Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu.

[0054] The term "has" or "having" is intended to mean that the peptide consists of the given amino acid sequence.

[0055] The present invention provides a peptide which comprises the sequence DNIMVTFRNQASRPY and has one of the following sequences: SEQ ID No. 17, 18, 19, 25, 26, 27, 29, 30 or 31.

[0056] The peptide may have one of the following sequences: SEQ ID No. 17, 18, 25 or 26.

[0057] The peptide may have SEQ ID No. 17 or 18.

[0058] The peptide may have SEQ ID No. 17.

[0059] The present invention also provides a peptide which comprises the sequence PRCLTRYSSSFVNME and has one of the following sequences: SEQ ID No. 1, 2, 3, 5, 7, 9, 10, 11 or 13.

[0060] The peptide may have one of the following sequences: SEQ ID No. 1, 2, 9 or 10.

[0061] The peptide may have SEQ ID No. 1 or 2.

[0062] The peptide may have SEQ ID No. 1.

FACTOR VIII

[0063] The sequences DNIMVTFRNQASRPY and PRCLTRYSSSFVNME which form the central portion of the peptides of the invention are both derivable from factor VIII.

[0064] Factor VIII participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca²⁺ and phospholipids, converts factor X to the activated form Xa.

[0065] The factor VIII gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity.

[0066] The complete 186,000 base-pair sequence of the human factor VIII gene was elucidated in the mid 1980s (Gitschier et al (1984) Nature 312 326-330). At the same time, DNA clones encoding the complete 2351 amino acid sequence were used to produce biologically active factor VIII in cultured mammalian cells (Wood et al (1984) Nature 312:330-337). The complete 2,351 amino acid sequence for human factor VIII is given in SEQ ID No. 33.

SOLUBILITY

[0067] The peptide of the first embodiment of the invention is a modified form of one of the following peptides:

DNIMVTFRNQASRPY
PRCLTRYSSSFVNME

[0068] These peptides have already been shown to act as epitopes and be tolerogenic *in vivo* (See examples and International patent application No PCT/GB2008/003996).

[0069] It has since come to light that solubility is an important consideration in peptide-mediated tolerance induction.

[0070] The present inventors have found that solubility may be improved by incorporation of a Glycine spacer at both ends, followed by combinations of two additional amino acids which may be Lysine (K) and/or Glutamic acid (E) at both N and C termini.

The possible combination at a given terminus is therefore KK, KE, EK or EE.

[0071] The modified peptides of the present invention therefore have 6 additional amino acids (3 at each end) than the parent DNIVM and PRCLT peptides.

[0072] The peptides of the present invention have the general formula:

XXGDNIMVTFRNQASRPYGXX or

XXGPRCLTRYSSFVNMEGXX

wherein X is either Lysine or Glutamic acid.

[0073] The modified peptide may be more soluble than the parent (unmodified) peptide. The modified peptide may have 2, 3, 4, or 5-fold greater solubility than the parent peptide. The peptide may be soluble at concentrations of up to 0.5 mg/ml, 1 mg/ml, or 5 mg/ml.

TOLERANCE

[0074] T cell epitopes play a central role in the adaptive immune response to any antigen, whether self or foreign. The central role played by T cell epitopes in hypersensitivity diseases (which include allergy, autoimmune diseases and transplant rejection) has been demonstrated through the use of experimental models. It is possible to induce inflammatory or allergic diseases by injection of synthetic peptides (based on the structure of T cell epitopes) in combination with adjuvant.

[0075] By contrast, it has been shown to be possible to induce immunological tolerance towards particular antigens by administration of peptide epitopes in soluble form. Administration of soluble peptide antigens has been demonstrated as an effective means of inhibiting disease in experimental autoimmune encephalomyelitis (EAE - a model for multiple sclerosis (MS)) (Metzler and Wraith (1993) *Int. Immunol.* 5:1159-1165; Liu and Wraith (1995) *Int. Immunol.* 7:1255-1263; Anderton and Wraith (1998) *Eur. J. Immunol.* 28:1251-1261); and experimental models of arthritis, diabetes, and uveoretinitis (reviewed in Anderton and Wraith (1998) as above). This has also been demonstrated as a means of treating an ongoing disease in EAE (Anderton and Wraith (1998) as above).

[0076] Tolerance is the failure to respond to an antigen. Tolerance to self-antigens is an essential feature of the immune system, when this is lost, autoimmune disease can result. The adaptive immune system must maintain the capacity to respond to an enormous variety of infectious agents while avoiding autoimmune attack of the self-antigens contained within its own tissues. This is controlled to a large extent by the sensitivity of immature T lymphocytes to apoptotic cell death in the thymus (central tolerance). However, not all self-antigens are detected in the thymus, so death of self-reactive thymocytes remains incomplete. There are thus also mechanisms by which tolerance may be acquired by mature self-reactive T lymphocytes in the peripheral tissues (peripheral tolerance). A review of the mechanisms of central and peripheral tolerance is given in Anderton et al (1999) (*Immunological Reviews* 169:123-137).

[0077] In haemophilia A, patients have a defect in the factor VIII gene. This means that factor VIII is not recognised as a "self" antigen by the immune system. When factor VIII is administered during coagulation factor replacement therapy, therefore, an alloimmune response is generated to the foreign protein, leading to the production of FVIII inhibitor antibodies.

[0078] The peptides of the present invention are capable of inducing tolerance to factor VIII such that when FVIII is administered prophylactically, it does not induce an immune response and FVIII inhibitors do not develop; and when it is administered therapeutically, ongoing FVIII inhibitor production is reduced or inhibited.

[0079] Acquired haemophilia is an autoimmune disease in which tolerance to factor VIII breaks down. In this case, peptides of the present invention may be administered to reinstate tolerance to this self-protein and curtail the pathogenic immune response.

[0080] Tolerance may result from or be characterised by the induction of anergy in at least a portion of CD4+ T cells. In order to activate a T cell, a peptide must associate with a "professional" APC capable of delivering two signals to T cells. The first signal (signal 1) is delivered by the MHC-peptide complex on the cell surface of the APC and is received by the T cell via the TCR. The second signal (signal 2) is delivered by costimulatory molecules on the surface of the APC, such as CD80 and CD86, and received by CD28 on the surface of the T cell. It is thought that when a T cell receives signal 1 in the absence of signal 2, it is not

activated and, in fact, becomes anergic. Anergic T cells are refractory to subsequent antigenic challenge, and may be capable of suppressing other immune responses. Anergic T cells are thought to be involved in mediating T cell tolerance.

[0081] Without wishing to be bound by theory, the present inventors predict that peptides which require processing before they can be presented in conjunction with MHC molecules do not induce tolerance because they have to be handled by mature antigen presenting cells. Mature antigen presenting cells (such as macrophages, B cells and dendritic cells) are capable of antigen processing, but also of delivering both signals 1 and 2 to a T cell, leading to T cell activation. Apitopes, on the other hand, will be able to bind class II MHC on immature APC. Thus they will be presented to T cells without costimulation, leading to T cell anergy and tolerance.

[0082] Of course, apitopes are also capable of binding to MHC molecules at the cell surface of mature APC. However, the immune system contains a greater abundance of immature than mature APC (it has been suggested that less than 10% of dendritic cells are activated, Summers et al. (2001) Am. J. Pathol. 159: 285-295). The default position to an apitope will therefore be anergy/tolerance, rather than activation.

[0083] The induction of tolerance to FVIII can be monitored *in vivo* by looking for a reduction in the level of:

1. (i) FVIII inhibitory antibodies;
2. (ii) CD4+ T cells specific for FVIII
3. (iii) B cells capable of secreting FVIII inhibitory antibodies

by techniques known in the art.

[0084] The induction of tolerance can therefore also be monitored by various techniques including:

1. (a) the induction of anergy in CD4+ T cells (which can be detected by subsequent challenge with FVIII *in vitro*);
2. (b) changes in the CD4+ T cell population, including
 1. (i) reduction in proliferation;
 2. (ii) down-regulation in the production of IL-2, IFN- γ and IL-4; and
 3. (iii) increase in the production of IL-10.

[0085] As used herein, the term "tolerogenic" means capable of inducing tolerance.

COMPOSITION

[0086] The present invention also relates to a composition, such as a pharmaceutical composition comprising one or more peptide(s) according to the invention.

[0087] The composition may comprise a modified form of the peptide DNMVTFRNQASRPY and a modified form of the peptide PRCLTRYSSFNME.

[0088] The peptide may comprise a plurality of peptides, for example, two, three, four, five or six peptides.

[0089] The composition of the present invention may be for prophylactic or therapeutic use.

[0090] When administered for prophylactic use, the composition may reduce or prevent the generation of an immune response to FVIII. The level of immune response is less than would have been obtained in the patient had not been treated with the composition. The term "reduce" indicates that a partial reduction in immune response is observed, such as a 50%, 70%, 80% or 90% reduction in the response that would have been observed in the patient had not been treated with the composition (or in the response observed in an untreated patient over the same time-frame). The term "prevent" indicates that no appreciable immune response to FVIII is observed.

[0091] When administered for therapeutic use, the composition may suppress an already ongoing immune response to FVIII. The term "suppress" indicates a reduction in the level of an on-going immune response, compared to the level before peptide treatment, or the level which would have been observed at the same time point had the treatment not been given.

[0092] Treatment with the composition of the present invention may cause a reduction in levels of any or all of the following:

1. (i) FVIII inhibitory antibodies;
2. (ii) CD4+ T cells specific for FVIII
3. (iii) B cells secreting FVIII inhibitory antibodies.

[0093] Detection of all these factors can be carried out by techniques known in the art, such as ELISA, Flow cytometry, chromogenic clotting assay etc.

[0094] Treatment with the composition of the present invention may also or alternatively cause anergy in CD4+ T cells specific for FVIII. Anergy can be detected by for example subsequent challenge with FVIII *in vitro*.

[0095] It is important to bear in mind that not all immune responses to FVIII are pathogenic. Non-inhibitory anti-FVIII antibodies may be found in haemophilia patients without inhibitors (Moreau *et al* (2000) Blood 95:3435-41) and approximately 15% of healthy blood donors (Algiman *et al* (1992) 89:3795-9).

[0096] FVIII inhibitors may be detected by the Nijmegen modification of the clotting Bethesda assay, in which the ability of the patient's plasma to inactivate FVIII in normal plasma is tested. A Bethesda unit is defined as the amount of antibody that neutralizes 50% of plasma FVIII activity, and titres of 0.6BU or greater suggest the presence of antibody.

[0097] Inhibitors are generally classified as low titre if the level is <5 BU and high titre if ≥ 5 BU.

[0098] The level of circulating FVIII inhibitory antibodies may be reduced to 90%, 75%, 50%, 20%, 10% 5% of the level of antibodies which would have been observed had the patient not received treatment.

[0099] The level of circulating FVIII inhibitory antibodies may be reduced to 5, 4, 3, 2, 1 or 0.5 BU.

[0100] The peptides and composition of the invention may increase the amount or proportion of therapeutically administered FVIII which is available to aid clotting in a patient. This is due to the reduction in FVIII inhibitors which may effectively remove a proportion of FVIII from exerting its therapeutic function. The peptide or composition of the invention may increase the amount of available FVIII by, for example, 10%, 25%, 50% 75% or 100%.

[0101] The peptides and composition of the invention may thus reduce the amount of FVIII which needs to be administered to aid clotting in a patient.

FORMULATION

[0102] The composition may be prepared as an injectable, either as liquid solution or suspension; solid form suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the peptides encapsulated in liposomes. The active ingredients may be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline (for example, phosphate-buffered saline), dextrose, glycerol, ethanol, or the like and combinations thereof.

[0103] In addition, if desired, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents and/or pH buffering agents. Buffering salts include phosphate, citrate, acetate, hydrochloric acid and/or sodium hydroxide may be used for pH adjustment. For stabilisation, disaccharides may be used such as sucrose or trehalose.

[0104] If the composition comprises a plurality of peptides, the relative ratio of the peptides may be approximately equal. Alternatively the relative ratios of each peptide may be altered, for example, to focus the tolerogenic response on a particular sub-set of autoreactive T-cells or if it is found that one peptide works better than the others in particular HLA types.

[0105] After formulation, the composition may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C, or it may be freeze-dried.

[0106] Conveniently the composition is prepared as a lyophilized (freeze dried) powder. Lyophilisation permits long-term storage

in a stabilised form. Lyophilisation procedures are well known in the art, see for example <http://www.devicelink.com/ivdt/archive/97/01/006.html>. Bulking agents are commonly used prior to freeze-drying, such as mannitol, dextran or glycine.

[0107] The composition may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, sublingual, intranasal, intradermal or suppository routes or implanting (e.g. using slow release molecules).

[0108] The composition may advantageously be administered via intranasal, subcutaneous or intradermal routes.

[0109] The peptide and composition of the invention may be used to treat a human subject. The subject may have haemophilia A, in particular severe haemophilia A. The subject may be genetically deficient in FVIII. The subject may have acquired haemophilia. The subject may have inhibitory anti-FVIII antibodies.

[0110] The subject may be undergoing or about to undergo coagulant replacement therapy with FVIII.

[0111] The subject may be undergoing or about to undergo therapy with by-passing agents [with or without coagulant replacement therapy with FVIII].

[0112] The subject may be undergoing or about to undergo gene therapy with the FVIII gene.

[0113] The subject may be an HLA-haplotype which is associated with a predisposition to develop inhibitory anti-FVIII alloantibodies or autoantibodies. The subject may express HLA-DR2. Methods for determining the HLA haplotype of an individual are known in the art.

[0114] Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient.

[0115] In a preferred embodiment a "dose escalation" protocol may be followed, where a plurality of doses is given to the patient in ascending concentrations. Such an approach has been used, for example, for phospholipase A2 peptides in immunotherapeutic applications against bee venom allergy (Müller et al (1998) J. Allergy Clin Immunol. 101:747-754 and Akdis et al (1998) J. Clin. Invest. 102:98-106).

KITS

[0116] Conveniently, if the composition comprises a plurality of peptides, they may be administered together, in the form of a mixed composition or cocktail. However, there may be circumstances in which it is preferable to provide the peptides separately in the form of a kit, for simultaneous, separate, sequential or combined administration.

[0117] The kit may also comprise mixing and/or administration means (for example a vapouriser for intranasal administration; or a syringe and needle for subcutaneous/intradermal dosing). The kit may also comprise instructions for use.

[0118] The pharmaceutical composition or kit of the invention may be used to treat and/or prevent a disease.

[0119] In particular, the composition/kit may be used to treat and/or prevent anti-FVIII inhibitor formation in haemophilia A or acquired haemophilia patients. The composition/kit may be used to treat haemophilia impaired by the presence of neutralising FVIII antibodies.

HAEMOPHILIA A

[0120] Haemophilia A (classic haemophilia), is caused by the deficiency of Factor FVIII.

[0121] Haemophilia A has an estimated incidence of 1 in 10,000 males, while haemophilia B is estimated to occur in one in 40,000 males. Approximately 1 woman in 5,000 is a carrier for haemophilia A, and 1 in 20,000 is a carrier of haemophilia B. Haemophilia is typically divided into three classes: severe, moderate and mild, based on the level of clotting factor in the blood. In

severe haemophilia, there is less than 1 percent of normal clotting factor. The degree of severity tends to be consistent from generation to generation.

[0122] Contrary to popular belief, minor cuts and wounds do not usually present a threat to haemophiliacs. Rather, the greatest danger comes from spontaneous bleeding that may occur in joints and muscles. This is most prone to occur during years of rapid growth, typically between the ages of 5 and 15 years.

[0123] Repeated spontaneous bleeding in joints may cause arthritis, and adjacent muscles become weakened. Pressure on nerves caused by the accumulation of blood may result in pain, numbness, and temporary inability to move the affected area.

[0124] Haemophilia A is usually diagnosed with a blood test to determine the effectiveness of clotting and to investigate whether the levels of clotting factors are abnormal.

[0125] The development of purified clotting factors in the 1970s, isolated from donated blood, significantly improved the long-term outlook for haemophiliacs. Mild to moderate haemophiliacs can use treatment with FVIII on an *ad hoc* basis, whereas severe haemophiliacs may require regular, indefinite treatment.

[0126] Previously, patients were given factor VIII concentrates pooled from thousands of plasma donations. This leads to significant problems of contamination with viral pathogens, particularly the human immunodeficiency virus and the hepatitis viruses. Monoclonal antibody purification techniques, heat inactivation, and virucidal detergent treatments have rendered plasma-derived concentrates relatively safe.

[0127] Recombinant DNA technology has now provided a series of synthetic products, such as Recombinate™ and Kogenate™. Kogenate is made using baby hamster kidney cells expressing human factor VIII. The resulting factor is highly purified, eliminating any possibility of transmission of virus from plasma.

[0128] The peptide or composition of the present invention may be administered before and/or during factor VIII replacement therapy.

[0129] Haemophilia A is an ideal disease target for gene therapy since i) it is caused by a mutations in a single identified gene, ii) a slight increase in clotting factor levels *in vivo* can convert severe haemophilia into milder disease, and iii) current replacement therapies are considered suboptimal. Also, there is a wide range of safety if there is an "overshoot" of desired level of coagulation activity.

[0130] Unfortunately, to date the promise of gene therapy as a cure for haemophilia has not been realized, primarily because of difficulties in finding a gene delivery system which is sufficiently non-immunogenic to allow for long term expression of the clotting factor.

[0131] The peptides of the present invention is also suitable for tolerising a subject prior to gene therapy with factor VIII and/or managing FVIII inhibitor formation in a patient following gene therapy.

ACQUIRED HAEMOPHILIA

[0132] Acquired haemophilia is characterised by the presence of autoantibody inhibitors against FVIII in individuals with previously normal coagulation. It is a rare condition, with an estimated incidence of 1-3 per million population per year. The mortality rate associated with acquired autoantibody inhibitors approaches 25% versus the substantially lower risk of death in those with alloantibodies.

[0133] Compared to alloantibody inhibitor patients, acquired haemophilia is characterized by: (1) a more severe bleeding pattern; (2) higher incidence in older population; (3) occurrence in conjunction with identifiable underlying autoimmune diseases, lymphoproliferative or solid tumor malignancies, pregnancy, and use of certain antibiotics such as penicillin and sulfonamides in approximately 50% of cases; and (4) *in vitro* inhibitor activity that follow a type II pharmacokinetic pattern with incomplete neutralization of the targeted clotting factor activity by the autoantibody, typically resulting in residual factor VIII levels ranging between 2%-18% in patient plasma.

[0134] The peptide or composition of the present invention may be administered to a patient with acquired haemophilia, or to a

patient believed to be at risk of developing acquired haemophilia due to, for example:

1. i) imminent treatment with, for example penicillin or a sulfonamide
2. ii) progression of a tumour or other malignancy
3. iii) imminent or early pregnancy.

[0135] The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

EXAMPLES

Example 1 - Investigating the solubility of FVIII-derived peptides.

[0136] A total of 32 peptides were tested: 16 of which were based on the FVIII peptide PRLTRYSSFVNME ("PRLT"); and 16 of which were based on the FVIII peptide DNIMVTFRNQASRPY ("DNIMV"). The peptides are summarised in Tables 1 and 2 below.

Table 1 - PRLT-derived peptides

Peptide No	Sequence	SEQ ID No.
1	Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys	1
2	Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu	2
3	Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys	3
4	Lys-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Glu	4
5	Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys	5
6	Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Glu	6
7	Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Lys	7
8	Glu-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Glu-Glu	8
9	Lys-Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys	9

Peptide No	Sequence	SEQ ID No.
10	Lys- Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Lys-Glu	10
11	Lys- Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Glu-Lys	11
12	Lys- Glu-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Glu-Glu	12
13	Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Lys-Lys	13
14	Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Lys-Glu	14
15	Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Glu-Lys	15
16	Glu-Lys-Gly-Pro-Arg-Cys-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser- Phe-Val-Asn-Met-Glu-Gly-Glu-Glu	16

Table 2 - DNIMV-derived peptides

Peptide No	Sequence	SEQ ID No.
17	Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala- Ser-Arg-Pro-Tyr-Gly-Lys-Lys	17
18	Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala- Ser-Arg-Pro-Tyr-Gly-Lys-Glu	18
19	Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala- Ser-Arg-Pro-Tyr-Gly-Glu-Lys	19
20	Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala- Ser-Arg-Pro-Tyr-Gly-Glu-Glu	20
21	Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala- Ser-Arg-Pro-Tyr-Gly-Lys-Lys	21

Peptide No	Sequence	SEQ ID No.
22	Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu	22
23	Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys	23
24	Glu-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu	24
25	Lys-Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys	25
26	Lys- Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu	26
27	Lys- Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys	27
28	Lys- Glu-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu	28
29	Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys	29
30	Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Glu	30
31	Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Lys	31
32	Glu-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Glu-Glu	32

[0137] A stock solution of each test peptide of 20mg/mL was prepared in DMSO. A stock solution of the control peptide, an MBP-derived peptide known as 4Y was also prepared in DMSO. Peptide 4Y has the sequence Ac-ASQYRPSQR. It is structurally dissimilar to the test peptides but is known to be sufficiently soluble for application as a tolerising antigen.

[0138] Sequential dilutions of a 40µL volume of peptide solution were made by adding water in a 96-well plate to give concentrations of 10, 5, 2.5 and 1.25 mg/mL

[0139] The plates were left at room temperature for 1 hour to allow any precipitate to form and then centrifuged at 14,800rpm for 10 minutes to separate precipitated/colloidal peptide from truly dissolved solute.

[0140] A 2µL sample from the very top of each tube was removed for analysis. Absorbance was measured at a wavelength of 280nm and concentration (mg/mL) was calculated.

[0141] The results are shown in Figure 1. Some tagged peptides demonstrated a solubility equivalent to 4Y, even at high concentration. Peptides coded green were as soluble as control peptide 4Y, peptides coded red were poorly soluble, and one peptide coded amber had intermediate solubility.

Example 2 - Direct dissolution of tagged peptides in aqueous solvent at clinically relevant concentration

[0142] For each test peptide and the parent peptides (PRCLT and DNIMV) two tubes were prepared at 4mg/mL in either DMSO (control) or PBS.

[0143] Each tube was spun at full speed in a mini-centrifuge for 5 minutes. A 10µL sample was removed from the top of each solution and the molecular weight and coefficient of absorption was recorded for each peptide.

[0144] The absorbance of the supernatant was measured using NanoDrop and the concentration calculated. The actual concentration was compared to the expected value of 4mg/mL and the results are shown in Figure 2. In this Figure, greater disparity between the actual and expected concentration corresponds to lower relative solubility.

[0145] As shown in Figure 2, the tagged peptides SEQ ID No. 1, 2, 9, 10, 17, 18, 25 and 26 all had improved solubility in PBS compared to the parent peptides.

Example 3 - The tagged peptides act as apitopes

[0146] HLA-DR2 transgenic mice were primed with the parent peptides PRCLT or DNIMV. Spleen and lymph nodes were then harvested, and after CD4 purification, cells were restimulated with 1ug/ml human recombinant FVIII. After fusion with BW5147 cells, the resulting clones were expanded and 'screened' for specificity to DNIMV or PRCLT. This is performed by incubating hybridoma cells with 5×10^4 DR2-positive antigen presenting cells (MGAR cell line) and 10ug/ml PRCLT/DNIMV or media for 48 hours. The supernatants were then analysed for IL-2 production by ELISA.

[0147] Clones which produced IL-2 specifically when incubated with peptide were expanded and screened again with FVIII (at 1ug/ml).

[0148] Clones which produced IL-2 in response to both FVIII and peptide were then used to assess whether the modified DNIMV and PRCLT peptides are apitopes i.e. whether they are capable of binding to an MHC molecule and being presented to a T cell by both fixed and fresh APC.

[0149] 5×10^4 hybridoma cells were incubated with 5×10^4 fresh or fixed MGAR cells, and 10ug/ml of peptide, 1ug/ml FVIII or media for 48 hours. Supernatants were then analysed for IL-2 using ELISA. The results are shown for PRCLT in Figure 3a and for DNIMV in Figure 3b.

[0150] All of the tagged peptides were capable of being presented by fixed antigen presenting cells, indicating that they are all apitopes like the parent peptides PRCLT and DNIMV.

Example 4: Ex vivo T cell tolerance

[0151] To determine if modified apitopes were capable of regulating T cell responses to parent peptides, male HLA-DR2 transgenic mice were treated with 3x100µg peptide (peptides SEQ ID No. 1, 2, 17 or 18) or PBS as a control, and then immunised with 100µg of each of the parent peptides (PRCLT and DNIMV) in complete Freund's Adjuvant. Ten days later, draining lymph nodes and spleens were collected and stimulated *in vitro* with either PRCLT or DNIMV. The results are shown in Figures 4 (PRCLT) and 5 (DNIMV). Treatment with modified peptides SEQ ID No. 1 or SEQ ID No. 2 reduces T cell responses to PRCLT and treatment with modified peptides SEQ ID No. 17 or SEQ ID No. 18 reduces T cell responses to DNIMV. Thus the modified peptides are able to reduce an immune response from mice immunised with the parent peptide.

Example 5: Ex vivo T cell tolerance

[0152] In order to determine if the effect of modified epitopes on the regulation of T cell responses to parental peptides extended to regulating responses to FVIII, female HLA-DR2 transgenic mice were treated with 3x100µg peptide (peptides SEQ ID No. 1 or SEQ ID No. 17), and then primed with 100µg of each of the parent peptides (PRCLT and DNIMV) in complete Freund's Adjuvant. Ten days later, draining lymph nodes were collected and stimulated *in vitro* with either PRCLT, DNIMV or recombinant FVIII. The results are shown in Figure 6. Peptide SEQ ID no 1 significantly ($p<0.01$) reduced the T cell response to the PRCLT peptide. Peptide SEQ ID no 17 significantly ($p<0.02$) reduced the T cell response to DNIMV.

[0153] Peptide SEQ ID No.1 regulated responses to PRCLT and peptide SEQ ID No.17 regulated responses to DNIMV. There was also some reduction, which was non-significant, in response to FVIII with individual peptides. To enhance efficacy of the peptides against FVIII immune responses a combination of modified DNIMV and modified PRCLT were used in further experiments.

Example 6: Antibody generation prevention with a dose escalation of a combination of PRCLT and DNIMV modified peptides

[0154] Male HLA-DR2 transgenic mice were treated with the combination of peptide SEQ ID No. 1 and peptide SEQ ID No. 17 following a dose escalation protocol. Six injections of the combination were given at the following dose: 0.1; 1.0; 10 and 3x100 µg (for each peptide in the combination).

[0155] Animals were then primed weekly with 1µg recombinant human FVIII and a concurrent treatment (3 days after rFVIII immunisation) with a combination of peptides SEQ ID No.1/SEQ ID No.17 (100 µg each) and the generation of anti-FVIII antibodies analysed from blood samples taken after 4 and 8 FVIII immunisations (day 28, Figure 7a; day 56, Figure 7b, respectively). Sera were titrated and analysed by direct ELISA. The antibody titre for unimmunised mice was negative in all cases, whereas anti-FVIII antibody was considered present in the sera of treated mice where binding ratio (using negative sera to calculate the ratio) was greater than 1.9. Results are shown in Figure 7 a and b for day 28 and day 56 of the experiment, respectively.

[0156] In addition, neutralizing FVIII antibodies were measured on day 56. FVIII neutralizing antibodies were determined using a chromogenic method. Briefly, samples were mixed with 1 IU/ml FVIII and coagulation was initiated by addition of FIX, FX, Trombin, CaCl_2 and phospholipids. After incubation the amount of generated FXa was determined by addition of the chromogenic substrate S-2760 and the OD signal was measured. The OD signal is proportional to the FVIII activity in the samples and is compared to samples containing a known amount of FVIII and no neutralizing antibodies. The % remaining activity of the test sample was calculated compared to the reference samples and expressed in Bethesda like units and shown in Figure 8. Mice treated with peptides SEQ ID1 and SEQ ID17 had a significantly lower level of neutralizing anti-FVIII antibodies than mice treated with PBS.

Example 7: Ex vivo T cell tolerance using a dose escalation of a combination of PRCLT and DNIMV modified peptides

[0157] Male/female DR2 mice were treated with the combination of peptides SEQ ID No1/SEQ ID No17 following a dose escalation protocol as described in Example 6.

[0158] Animals were primed with 100µg PRCLT and 100µg DNIMV in CFA. Ten days later draining lymph nodes cells and splenocytes were isolated and restimulated *in vitro* with recombinant human FVIII.

[0159] T cell responses were assessed by proliferation assays (Figure 9). A significant reduction of T cell responses to FVIII were seen across all concentrations of FVIII tested when the mice were treated with the combination of peptides SEQ ID No1 and SEQ ID No17.

Example 8: Suppression of neutralising antibody generation with a dose escalation of a combination of PRCLT and DNIMV modified peptides in a therapeutic animal model

[0160] HLA-DR2 transgenic mice were primed with 3µg rFVIII in CFA and three weeks after the immunisation treated with the combination of peptide SEQ ID No. 1 and peptide SEQ ID No. 17 following a dose escalation protocol. Six injections of the combination were given at the following dose: 0.1; 1.0; 10 and 3x100 µg (for each peptide in the combination). Control animals were treated with a non-related FVIII DR2-binding prostatic acid phosphatase (PAP) 133-152 peptide (sequence as described in patent PCT/US2006/031961, SEQ ID No. 15) using the same dose-escalation protocol. All animals received a boost immunization with 3µg rhFVIII in IFA five weeks after rFVIII immunisation and 4 days after the last round of peptide treatment. Generation of neutralising antibodies was analysed from plasma samples taken 3 weeks after the first FVIII immunisation and prior to any peptide treatment, at week 5 (prior to the FVIII boost immunisation and after the peptide treatment) and during a follow-up period at week 7, 9 and 13. Neutralising FVIII antibody levels in the plasma samples were determined as described in Example 6.

[0161] Results in figure 10 show that treatment with peptides SEQ ID No. 1 and SEQ ID No. 17 three weeks after immunisation with FVIII (Week 3) suppress the formation of neutralizing anti-FVIII antibodies significantly after the boost immunization (Week 5) compared to treatment with control peptide.

[0162] Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular immunology or related fields are intended to be within the scope of the following claims.

SEQ ID No.33

[0163]

1 mjaie|stc|ff lcllrfcfa tryylgave lswdymqsd| gelpvdarfp prvpksfpfn
61 tsvyvkk|tf velt|dhfni akprppwmgl lgptiqaevy dtvvtlknm ashpvs|hav
121 gvsywkaseg aeyddqtsqr ekeddkvfpq gshtyvqv| kengpmasdp lctysylsh
181 vdlvkdlnsg ligallvcre gslakektqt lkhfillfav fdegkswhse tknsimqdrd
241 aasarawpkm htvngyvns lpgligchrk svywhvigm|g tpevhsifi egh|flvrnh
301 rqa|leispi tftaqtlim dlqqlfch isshqhdgme ayvkvdscpe epqlmknne
361 eaedydddlf dsem|dvvrfd ddnspsfiq rsvakkhpk|t wvhya|eeee dwdyaplvla
421 pddrsyqsqy lnnppqrigr kykkvrfmay t|etfktrea iqhesgilgp llygevgdtl
481 liifknqasr pyniypg|it dvrp|ysrri pkgvkh|kdf piipgeifky kwtvtvedgp
541 tksdprcltr yyssfvnmer d|asgligpl licykesvdq| rgnqimsdkr nvlfsvfde
601 nrswylleni qrflpnpagv qledpefqas nimhsingy|v f|slqlsvcl hevaywyils
661 lgaqtdflsv ffsygtfkhk mvyedt|tf pfsgetvfms| menpgilw|l chnsdfrng
721 mtallkvssc dkntgdyyed syedisayl| sknnaieprs fsqnsrhpst r|kqfnatti
781 pendiekt|p wfahrtpmpk iqnvssd|l mllrqsptph| glslsd|qea kyetfsddps
841 pgaidnsnsl semthfrpql hhsqdmvftp esgl|rlne k|gttaatel kkl|dfkvsst
901 snnlstips d|laagtdnt sslgppsm|pv hyd|ql|dtl fgkksplte sggplslsee
961 nndskilesq lmsqesswg knvsstesgr lfk|krahgp| alltkdnalf kvsislktn
1021 ksnnsatnr kthidgpsl ienspsvwqn |lesdtefkk| v|plihdrml mdknata|l
1081 nhmsnktss knmemvqqk egpippdaqn |pmsffkmlf| l|esarwiqr thgknslnsg
1141 qgspkqlvs lgpeksvegq n|fseknkvv v|kgeftkdv| glkemvfpss n|lftnldn
1201 lhen|thnqe kkiqeeiekk etliqenvl| pqihvtg|k nfmkn|flls trqnvegsyd
1261 gayapvlqdf r|lndstnr k|khtahfskk geenleg|g n|tkqiveky acttrispnt
1321 sqqnfv|qrs kralkq|rip leetelekri |vddts|qws knmkhltpst ltqidyneke
1381 kgaitqspls dcltrshsp qanrsplia kvss|psirp| iyltrvlfqd nshlpaasy
1441 rkkdsgvqes shflqgakkn n|slailtle mtgdqrevgs| l|gsatnsvt ykkventvlp
1501 kpd|pkts|gk vellpkvhiy qkdlfptets ngspghdlv| egsl|lqgteg aikwneanrp
1561 gkvpf|rvat essaktpskl l|plawdnhy gtq|pkeewk| sqekspekta fkkkdtilsl
1621 nacesnhaia ainegqnkpe |evtwakqqr terlcsqnpp| vlkrh|qreit rtlqsdqee
1681 idyddtisve mkkedfdi|d edenqsprsf qk|ktrhyfia| averlwdygm sssphvlrnr
1741 aqsgsvpqfk kvvqeftdg sftqplyrge lneh|gilgp| yiraavedni mvtfmqasr
1801 pysfysslis yeedqrqgae prknfvkpne tky|fwkvqh| hmaptkdefd ckawayfsdv
1861 dlekdvhsgl igpll|vchtn tlnpahgrqv tvqefalft| ifdetkswyf tenmernra
1921 pcniqmedpt fkenyrfhai ngyimdtlpg l|vmaqdrir| wyllsmgsne nihsihfsgn
1981 v|vrk|keey kmaly|lypg v|etvemp|ps kagiwrvecl| igehl|hagms t|fivysnkc

2041 q|plgmasgh |rdqitasg qygqwapkla r|hysgsina| wstkepfswi kvdlapmii
2101 h|k|tqgarq kfsslyisqf |lmysldgkk wq|yrgnstg| t|mvffgnvd ssgikhnlfn
2161 p|liaryirl h|thysirst lrmewmgcdl nscsmplgme| skaisdaqit assyftnmfa
2221 twspskarih lqgrsnawrp qvnrpkewlq vdfqktmkvt| gvttqgvksl ltsmyvkefl
2281 issqdghqw t|ffqngkvk v|qgnqdsft pvvnsl|dpl ltryl|hpq swvhqialrm
2341 evlgceaql y

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US2006031961W \[0036\] \[0160\]](#)
- [WO0216410A \[0047\] \[0049\]](#)

- [CE2008003996W \[0058\]](#)

Non-patent literature cited in the description

- REDING et al. Haemophilia, 2006, vol. 12, 630-36 [0010]
- HAY et al. Seminars in Thrombosis and Hemostasis, 2005, vol. 32, 15-21 [0013]
- ACHARYADIMICHELE Best Practice & Research Clinical Haematology, 2006, vol. 19, 51-66 [0014]
- DIMICHELE J Thromb Haemost, 2007, vol. 5, 143-50 [0016]
- ROBERGE JY et al. Science, 1995, vol. 269, 202-204 [0039]
- CREIGHTON Proteins Structures And Molecular Principles WH Freeman and Co 1983 0000 [0039]
- GITSCHIER et al. Nature, 1984, vol. 312, 326-330 [0066]
- WOOD et al. Nature, 1984, vol. 312, 330-337 [0066]
- METZLERWRAITH Int. Immunol., 1993, vol. 5, 1159-1165 [0075]
- LIUWRAITH Int. Immunol., 1995, vol. 7, 1255-1263 [0075]
- ANDERTONWRAITH Eur. J. Immunol., 1998, vol. 28, 1251-1261 [0075]
- ANDERTON et al. Immunological Reviews, 1999, vol. 169, 123-137 [0076]
- SUMMERS et al. Am. J. Pathol., 2001, vol. 159, 285-295 [0082]
- MOREAU et al. Blood, 2000, vol. 95, 3435-41 [0095]
- MÜLLER et al. J. Allergy Clin Immunol., 1998, vol. 101, 747-754 [0115]
- AKDIS et al. J. Clin. Invest., 1998, vol. 102, 98-106 [0115]

Patentkrav

1. Peptid, der omfatter den FVIII-afledte sekvens
DNIMVTFRNQASRPY, hvilket peptid (a) har formlen

5 XXGDNIMVTFRNQASRPYGXX

hvor X er enten lysin eller glutaminsyre; og

(b) har en af følgende sekvenser:

KKGDNIMVTFRNQASRPYGKK (SEQ ID NO: 17)

KKGDNIMVTFRNQASRPYGKE (SEQ ID NO: 18)

10 KKGDNIMVTFRNQASRPYGKE (SEQ ID NO: 19)

KEGDNIMVTFRNQASRPYGKK (SEQ ID NO: 25)

KEGDNIMVTFRNQASRPYGKE (SEQ ID NO: 26)

KEGDNIMVTFRNQASRPYGKE (SEQ ID NO: 27)

EKGDNIMVTFRNQASRPYGKK (SEQ ID NO: 29)

15 EKGDNIMVTFRNQASRPYGKE (SEQ ID NO: 30) og

EKGDNIMVTFRNQASRPYGKE (SEQ ID NO: 31).

2. Peptid, der omfatter den FVIII-afledte sekvens
PRCLTRYSSFVNME, hvilket peptid (a) har formlen

20 XXGPRCLTRYSSFVNMEGXX

hvor X er enten lysin eller glutaminsyre; og

(b) har en af følgende sekvenser:

KKGPRCLTRYSSFVNMEGKK (SEQ ID NO: 1)

KKGPRCLTRYSSFVNMEGKE (SEQ ID NO: 2)

25 KKGPRCLTRYSSFVNMEGEK (SEQ ID NO: 3)

EEGPRCLTRYSSFVNMEGKK (SEQ ID NO: 5)

EEGPRCLTRYSSFVNMEGEK (SEQ ID NO: 7)

KEGPRCLTRYSSFVNMEGKK (SEQ ID NO: 9)

KEGPRCLTRYSSFVNMEGKE (SEQ ID NO: 10)

30 KEGPRCLTRYSSFVNMEGEK (SEQ ID NO: 11) og

EKGPRCLTRYSSFVNMEGKK (SEQ ID NO: 13).

3. Sammensætning, der omfatter et antal peptider, herunder
et eller flere peptider ifølge krav 1 eller 2.

35

4. Sammensætning ifølge krav 3, der omfatter mindst ét
peptid ifølge krav 1 og mindst ét peptid ifølge krav 2.

5. Sammensætning ifølge krav 4, der omfatter et peptid med SEQ ID NO: 1 og et peptid med SEQ ID NO: 17.

5 6. Peptid ifølge krav 1 eller 2 eller sammensætning ifølge et hvilket som helst af kravene 3 til 5 til anvendelse til suppression eller forebyggelse af produktionen af antistoffer mod faktor VIII-inhibitor in vivo.

10 7. Peptid ifølge krav 1 eller 2 eller sammensætning ifølge et hvilket som helst af kravene 3 til 5 til anvendelse i en fremgangsmåde til behandling af hæmofili hos en person.

15 8. Peptid eller sammensætning til anvendelse ifølge krav 7, hvor personen har hæmofili A og gennemgår eller skal i gang med faktor VIII-substitutionsterapi og/eller FVIII-bypass-terapi.

20 9. Peptid eller sammensætning til anvendelse ifølge krav 7, hvor personen har eller er i risiko for at få erhvervet hæmofili.

10. Peptid eller sammensætning til anvendelse ifølge et hvilket som helst af kravene 7 til 9, hvor personen er HLA-DR2.

DRAWINGS

Figure 1

	PRCLT	DNIMV	
KK-KK	1	1	Further Investigation
KK-KE	2	1	
KK-EK	3	2	
KK-EE	4	2	
EE-KK	5	2	Further Investigation
EE-KE	6	2	
EE-EK	7	2	
EE-EE	8	2	
KE-KK	9	1	Further Investigation
KE-KE	10	1	
KE-EK	11	1	
KE-EE	12	1	
EK-KK	13	1	
EK-KE	14	1	
EK-EK	15	1	
EK-EE	16	1	

Figure 2




Figure 3a




Figure 3b




Figure 4




Figure 5




Figure 6






Figure7

Figure 7a: anti-FVIII antibody titres at day28:




Figure 7b: anti-FVIII antibody titres at day56:




Figure 8





Figure 9






Figure 10